right now, and also to talk about some of their favorite picks for their radar screens in case there is a pullback. Karen Andersen : One of my favorite ideas right now is actually Gilead. It's a large-cap biotech name. We assign it a narrow
Karen Andersen : I'm Karen Andersen , senior biotech analyst at Morningstar. With me today to discuss ..... for joining me, Lauren. Lauren Migliore : Good to be here, Karen . Andersen : So, just to recap 2011, it was a relatively light year for
Karen Andersen : I am Karen Andersen , senior biotechnology analyst at Morningstar. With me today ..... for joining us, Lauren. Lauren Migliore : Great to be here, Karen . Andersen : So maybe just to set some context in going into 2011, a couple
short term. More important, over the long term, we believe Crucell's vaccine platform and novel biologics manufacturing platform open the door to major new markets for Johnson & Johnson. Karen Andersen , CFA, contributed to this note.
AMGN, to emerge in the coming weeks. Given the timing of other acquisitions--such as Eli Lilly's LLY acquisition of ImClone--we think a deal could get done in September or October. Karen Andersen , CFA, contributed to this note.
solanezumab. However, we only project a 40% chance of approval for solanezumab, based on the scientific community's lack of understanding of the mechanism of Alzheimer's disease. Karen Andersen , CFA, contributed to this note.
and today it's my great pleasure to welcome back Karen Andersen , who is Senior Biotech Analyst here at Morningstar ..... Healthcare Observer. Karen, thanks for coming. Karen Andersen : Good to be here. Kobayashi-Solomon : And I just
and today it's my great pleasure to welcome back Karen Andersen who is senior biotech analyst here at Morningstar ..... Healthcare Observer . Karen, thanks for coming. Karen Andersen : My pleasure. Kobayashi-Solomon : So we did an
OptionInvestor, and today it's my great pleasure to welcome Karen Andersen , who's a senior analyst in charge of biotechnology stocks. Karen, thanks for coming. Karen Andersen : Pleasure to be here. Kobayashi-Solomon : Now
biologics. What are your views on this subject? Karen Andersen : Based on what we have seen so far in Europe, I ..... Laegeler : Right. Andersen : For Morningstar this is Karen Andersen , thanks for watching.